Serum neurofilament light chain in hereditary transthyretin amyloidosis: validation in real-life practice

References

• Carroll A, Dyck PJ, de Carvalho M, et al. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. J Neurol Neurosurg Psychiatry. 2022;93(6):668–678. doi:10.1136/jnnp-2021-327909.
   PubMedGoogle Scholar
• Conceição I, González-Duarte A, Obici L, et al. Red-flag symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2016;21(1):5–9. Mar doi:10.1111/jns.12153.
   PubMed Web of Science ®Google Scholar
• Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry. 2015;86(9):1036–1043. doi:10.1136/jnnp-2014-308724.
   PubMed Web of Science ®Google Scholar
• Coelho T, Maia LF, da Silva AM, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013;260(11):2802–2814. Nov doi:10.1007/s00415-013-7051-7.
   PubMed Web of Science ®Google Scholar
• Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21. doi:10.1056/NEJMoa1716153.
   PubMed Web of Science ®Google Scholar
• Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22–31. doi:10.1056/NEJMoa1716793.
   PubMed Web of Science ®Google Scholar
• Ericzon BG, Wilczek HE, Larsson M, et al. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation. 2015;99(9):1847–1854. Sep doi:10.1097/TP.0000000000000574.
   PubMed Web of Science ®Google Scholar
• Plante-Bordeneuve V. Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy. J Neurol. 2014;261(6):1227–1233. doi:10.1007/s00415-014-7373-0.
   PubMed Web of Science ®Google Scholar
• Adams D, Cauquil C, Labeyrie C. Familial amyloid polyneuropathy. Curr Opin Neurol. 2017;30(5):481–489. doi:10.1097/WCO.0000000000000476.
   PubMed Web of Science ®Google Scholar
• Conceição I, Costa J, Castro J, et al. Neurophysiological techniques to detect early small-fiber dysfunction in transthyretin amyloid polyneuropathy. Muscle Nerve. 2014;49(2):181–186. Feb doi:10.1002/mus.23901.
   PubMed Web of Science ®Google Scholar
• Gaetani L, Blennow K, Calabresi P, et al. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90(8):870–881. Aug doi:10.1136/jnnp-2018-320106.
   PubMed Web of Science ®Google Scholar
• Ticau S, Sridharan GV, Tsour S, et al. Neurofilament light chain as a biomarker of hereditary transthyretin-Mediated amyloidosis. Neurology. 2021;96(3):e412–e422. Jan 19 doi:10.1212/WNL.0000000000011090.
   PubMed Web of Science ®Google Scholar
• Kapoor M, Foiani M, Heslegrave A, et al. Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis. J Peripher Nerv Syst. 2019;24(4):314–319. doi:10.1111/jns.12350.
   PubMedGoogle Scholar
• Maia LF, Maceski A, Conceição I, et al. Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy. Amyloid. 2020;27(2):97–102. doi:10.1080/13506129.2019.1708716.
   PubMed Web of Science ®Google Scholar
• Louwsma J, Brunger AF, Bijzet J, et al. Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis. Amyloid. 2021;28(1):50–55. Mar doi:10.1080/13506129.2020.1815696.
   PubMed Web of Science ®Google Scholar
• Luigetti M, Di Paolantonio A, Guglielmino V, et al. Neurofilament light chain as a disease severity biomarker in ATTRv: data from a single-Centre experience. Neurol Sci. 2022;43(4):2845–2848. doi:10.1007/s10072-021-05850-7.
   PubMed Web of Science ®Google Scholar
• Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577–589. doi:10.1038/s41582-018-0058-z.
   PubMed Web of Science ®Google Scholar
• Ferreira-Atuesta C, Reyes S, Giovanonni G, et al. The evolution of neurofilament light chain in multiple sclerosis. Front Neurosci. 2021;15:642384. doi:10.3389/fnins.2021.642384.
   PubMedGoogle Scholar
• Strimbu K, Tavel JA. What are biomarkers? Curr Opin HIV AIDS. 2010;5(6):463–466. doi:10.1097/COH.0b013e32833ed177.
   PubMed Web of Science ®Google Scholar
• Loser V, Benkert P, Vicino A, et al. Serum neurofilament light chain as a reliable biomarker of hereditary transthyretin-related amyloidosis-A swiss reference center experience. J Peripher Nerv Syst. 2023;28(1):86–97. doi:10.1111/jns.12524.
   PubMed Web of Science ®Google Scholar
• Ticau S, Aldinc E, Polydefkis M, et al. Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study. Amyloid. 2023;20:1–11. doi:10.1080/13506129.2023.2232520.
   Google Scholar
• Bril V. NIS-LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. Eur Neurol. 1999;41(Suppl 1):8–13. doi:10.1159/000052074.
   PubMed Web of Science ®Google Scholar
• Murphy SM, Herrmann DN, McDermott MP, et al. Reliability of the CMT neuropathy score (second version) in Charcot-Marie-tooth disease. J Peripher Nerv Syst. 2011;16(3):191–198. Sep doi:10.1111/j.1529-8027.2011.00350.x.
   PubMed Web of Science ®Google Scholar
• Vinik EJ, Hayes RP, Oglesby A, et al. The development and validation of the norfolk QOL-DN, a new measure of patients’ perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther. 2005;7(3):497–508. doi:10.1089/dia.2005.7.497.
   PubMedGoogle Scholar
• Coutinho P, Martins da Silva A, Lopes Lima J, et al. Forty years of experience with type I amyloid neuropathy: review of 483 Cases. In: Glenner GG, Pinho e Costa P, Falcao de Freitas A, editors. Amyloid and Amyloidosis. Amsterdam: Excerpta Medica; 1980:88–98.
   Google Scholar
• Dyck PJ, Boes CJ, Mulder D, et al. History of standard scoring, notation, and summation of neuromuscular signs. A current survey and recommendation. J Peripher Nerv Syst. 2005;10(2):158–173. Jun doi:10.1111/j.1085-9489.2005.0010206.x.
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Kratz KM, Lehman KA, et al. The rochester diabetic neuropathy study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology. 1991;41(6):799–807. Jun doi:10.1212/wnl.41.6.799.
   PubMed Web of Science ®Google Scholar
• Sadjadi R, Reilly MM, Shy ME, et al. Psychometrics evaluation of Charcot-Marie-tooth neuropathy score (CMTNSv2) second version, using rasch analysis. J Peripher Nerv Syst. 2014;19(3):192–196. doi:10.1111/jns.12084.
   PubMed Web of Science ®Google Scholar
• Kleyweg RP, van der Meché FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve. 1991;14(11):1103–1109. doi:10.1002/mus.880141111.
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Wilczek HE, Nowak G, et al. Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years. Am J Transplant. 2007;7(11):2597–2604. doi:10.1111/j.1600-6143.2007.01969.x.
   PubMed Web of Science ®Google Scholar
• Weinhofer I, Rommer P, Zierfuss B, et al. Neurofilament light chain as a potential biomarker for monitoring neurodegeneration in X-linked adrenoleukodystrophy. Nat Commun. 2021;12(1):1816. doi:10.1038/s41467-021-22114-2.
   PubMed Web of Science ®Google Scholar
• Ladang A, Kovacs S, Lengelé L, et al. Neurofilament light chain concentration in an aging population. Aging Clin Exp Res. 2022;34(2):331–339. doi:10.1007/s40520-021-02054-z.
   PubMed Web of Science ®Google Scholar
• Benkert P, Meier S, Schaedelin S, et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol. 2022;21(3):246–257. doi:10.1016/S1474-4422(22)00009-6.
   PubMed Web of Science ®Google Scholar
• Sandelius Å, Zetterberg H, Blennow K, et al. Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology. 2018;90(6):e518–e524. doi:10.1212/WNL.0000000000004932.
   PubMed Web of Science ®Google Scholar
• Abdelhak A, Petermeier F, Benkert P, et al. Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study. Lancet Neurol. 2023;22(9):826–833. doi:10.1016/S1474-4422(23)00210-7.
   PubMed Web of Science ®Google Scholar
• Fukami Y, Iijima M, Koike H, et al. Association of serum neurofilament light chain levels with clinicopathology of chronic inflammatory demyelinating polyneuropathy, including NF155 reactive patients. J Neurol. 2021;268(10):3835–3844. doi:10.1007/s00415-021-10537-2.
   PubMed Web of Science ®Google Scholar
• van Lieverloo GGA, Wieske L, Verhamme C, et al. Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst. 2019;24(2):187–194. doi:10.1111/jns.12319.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Nukui T, Piao JL, et al. Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. Brain Behav. 2021;11(5):e02084.
   PubMed Web of Science ®Google Scholar
• Fernandes A, Coelho T, Rodrigues A, et al. Clinicopathological correlations of sural nerve biopsies in TTR Val30Met familial amyloid polyneuropathy. Brain Commun. 2019;1(1):fcz032.
   PubMedGoogle Scholar
• Rossor AM, Kapoor M, Wellington H, et al. A longitudinal and cross-sectional study of plasma neurofilament light chain concentration in Charcot-Marie-tooth disease. J Peripher Nerv Syst. 2022;27(1):50–57. doi:10.1111/jns.12477.
   PubMed Web of Science ®Google Scholar
• Disanto G, Barro C, Benkert P, et al. Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81(6):857–870. doi:10.1002/ana.24954.
   PubMed Web of Science ®Google Scholar
• Adams D, Algalarrondo V, Polydefkis M, et al. Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression. Orphanet J Rare Dis. 2021;16(1):411. doi:10.1186/s13023-021-01960-9.
   PubMed Web of Science ®Google Scholar
• Buxbaum JN, Dispenzieri A, Eisenberg DS, et al. Amyloid nomenclature 2022: update, novel proteins, and recommendations by the international society of amyloidosis (ISA) nomenclature committee. Amyloid. 2022;29(4):213–219. doi:10.1080/13506129.2022.2147636.
   PubMed Web of Science ®Google Scholar